Technetium(99mTc) Hydroxymethylenediphosphonate(Technetium(99mTc) Hydroxymethylenediphosphonate)

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

99mTc-HMDP、Technetium(99mTc) Hydroxymethylene diphosphonate、[99mTc]Hydroxymethylenebisphosphonate

+ [4]

靶点-

作用机制

SPECT(单光子发射计算机断层成像术增强剂)

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

骨病

非在研适应症

肿瘤

原研机构

Nihon Medi-Physics Co., Ltd.

在研机构

Nihon Medi-Physics Co., Ltd.

非在研机构

University of Cincinnati Physicians Co. LLC

最高研发阶段批准上市

首次获批日期

日本 (1982-12-15),

骨病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式CH6O7P2Tc

InChIKeySIJNDWFHVBDXDY-NLQOEHMXSA-N

CAS号385786-43-6

关联

1

项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的临床试验

NCT03812172

/ Active, not recruitingN/AIIT

Screening for Cardiac Amyloidosis with Nuclear Cardiology for Minority Populations

In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators will also explore differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

开始日期2019-05-15

申办/合作机构

Columbia University

[+5]

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的临床结果

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的转化医学

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的专利（医药）

登录后查看更多信息

66

项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的文献（医药）

2024-06-01·Radiological Physics and Technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

作者: Yasuno, Narumi ; Nakamura, Yuto

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

2024-01-01·Japanese Journal of Radiological Technology

Radiation Dose Considerations for Breast Sonographers Following <sup>99m</sup>Tc-HMDP Bone Scan Administration

Article

作者: Tsukada, Ryota ; Wagatsuma, Kei ; Suzuki, Hiroaki

PURPOSEPatients who were administered radiopharmaceuticals can be a source of radiation exposure to sonographers. This study aimed to identify factors associated with radiation exposure to breast sonographers from patients administered radiopharmaceuticals for bone scanning.METHODSThe exposure dose of six sonographers was measured during breast sonography in 59 patients administered ^99mTc-HMDP. We predicted the following factors to be related to exposure dose: time interval between administration and sonography, sonography examination time, estimated radioactivity at sonography, sonographer's years of experience, and patients' clinical data (age, renal function and surgical procedure). Spearman's rank correlation coefficient was used to examine the relationship between radiation dose and the aforementioned factors.RESULTSThe mean±standard deviation of the exposure dose for the sonographers was 9.3±3.8 µSv. The time interval between administering the radiopharmaceutical agent and sonography, the sonography examination time and estimated radioactivity at sonography were found to be factors related to the exposure of the sonographer. The exposure dose increased as a function of the shorter time interval, longer examination time and higher estimated radioactivity at sonography.CONCLUSIONThe time interval between drug administration and sonography, sonography examination time and estimated radioactivity at sonography contributed to the increased dose to breast sonographers. Although we considered that the exposure dose of sonographers would not possibly exceed the dose limit in the present study, we suggested that radiological technologists need to educate the physicians requesting sonography, and the sonographers about the radiation exposure in nuclear medicine.

2022-10-01·Injury3区 · 医学

99mTc-polyphosphonate labelling – Enhancement of a novel method for the quantification of osteogenic differentiation of MSCs in vitro

3区 · 医学

Article

作者: Schmidmaier, Gerhard ; Gotterbarm, Tobias ; Haberkorn, Uwe ; Grossner, Tobias ; Helbig, Lars

Bone tissue engineering is a fast-growing field in regenerative medicine. Consequently, there is a high demand for new, fast and reliable methods to track and quantify the osteogenic differentiation of cells. Recently, a novel method was published to non-destructively quantify the hydroxyapatite content of monolayer and 3-dimensional mesenchymal stem cell cultures using the ability of ⁹⁹^mTechnetium-methylene diphosphonate (MDP), a well-established tracer in clinical nuclear medicine, to bind to newly synthesized hydroxyapatite. In the present study, two other commonly used ⁹⁹^mTechnetium tracers, 2,3-dicarboxypropane-1,1-diphosphonate (DPD) and hydroxydiphosphonate (HDP), were evaluated to see if they could also be used for the same purpose. Furthermore, we investigated if labelling at various timepoints influenced the effectiveness of the labelling. The results were analysed using one-factor ANOVA followed by Bonferroni post-hoc testing. This revealed a highly significant difference between the three osteogenic groups at each timepoint compared to their corresponding negative controls. However, there was no statistically significant difference between the three different tracers (MDP, DPD, HDP) in the osteogenic groups. Therefore all three tracers are of similar value when quantifying the extracellular hydroxylapatite content in osteogenic stem cells cultures.

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨病	日本	Nihon Medi-Physics Co., Ltd.	1982-12-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	University of Cincinnati Physicians Co. LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	-	-	Osteogenic supplements (dexamethasone, L-ascorbic acid, and β-glycerol phosphate)	淵築觸齋壓鹽夢蓋憲鑰(築鑰築艱衊選淵襯鬱簾) = revealed no statistically significant difference at timepoint d21 between group 1 (219,103 cells counted) and group 7 (231,694 cells counted) 網鹽選鬱鏇餘鏇顧範遞 (襯淵餘顧壓鑰網鏇憲鑰 )	-	2023-08-28
				99mTc-HDP (Non-osteogenic controls)
SNMMI2022	N/A	-	-	99mTc-HDP (Osteogenic group OM)	範鑰壓顧糧鏇願鬱壓選(淵壓網遞願繭醖餘構鏇) = 網醖蓋襯範願襯簾製觸鹽窪淵積襯觸鬱窪糧蓋 (網鏇鏇醖齋願窪築範鬱 )	-	2022-08-08
				99mTc-HDP (Control group CTRL)	範鑰壓顧糧鏇願鬱壓選(淵壓網遞願繭醖餘構鏇) = 艱積製鏇夢衊積淵積構鹽窪淵積襯觸鬱窪糧蓋 (網鏇鏇醖齋願窪築範鬱 )
EANM2019	N/A	-	130	99mTc-HMDP	憲鹽衊廠鬱鏇糧觸齋簾(簾遞鹹鏇遞獵鑰蓋膚繭) = 壓繭願夢醖選餘廠鏇遞廠製淵繭繭襯蓋簾夢製 (鬱網願餘遞餘憲網醖襯, 1400) 更多	-	2019-09-18
EANM2019	N/A	骶髂关节炎	-	99mTc-HDP (MRI)	壓積觸範鏇膚簾網積願(鏇獵選遞鹹蓋齋觸觸憲) = 窪願衊繭鏇鏇範淵獵鏇衊範築鹽鏇觸鑰網製網 (淵醖夢蓋簾淵繭鹽遞遞 )	-	2019-09-18
SNMMI2019	N/A	转甲状腺素蛋白心脏淀粉样变	7	99m Tc-HMDP (Patients with cardiac ATTR)	觸壓糧鹽憲範憲繭窪淵(齋顧選網壓艱獵窪夢遞) = 遞衊鏇繭襯蓋衊膚醖網積鹽願選憲選觸願遞壓 (願淵繭範餘醖鹽鬱憲餘 )	积极	2019-05-21
				99m Tc-HMDP (Control group)	觸壓糧鹽憲範憲繭窪淵(齋顧選網壓艱獵窪夢遞) = 淵選獵餘築繭鏇簾糧壓積鹽願選憲選觸願遞壓 (願淵繭範餘醖鹽鬱憲餘 )
SNMMI2016	N/A	-	-	99mTc-HDP (DMEM low glucose)	餘範鹽齋夢廠壓壓鏇繭(鑰觸繭獵淵鏇鬱艱獵醖) = 醖構積齋窪鑰憲獵築遞簾糧醖廠遞積夢簾遞壓 (窪鏇積構製淵衊製夢獵 )	-	2016-05-24
				99mTc-HDP (DMEM high glucose)	餘範鹽齋夢廠壓壓鏇繭(鑰觸繭獵淵鏇鬱艱獵醖) = 鹹築選壓窪艱簾膚鏇糧簾糧醖廠遞積夢簾遞壓 (窪鏇積構製淵衊製夢獵 )
SNMMI2016	N/A	转甲状腺素蛋白心脏淀粉样变	-	99mTc-HMDP (wt-TTR-CA)	積艱鬱淵艱餘網鹽築衊(網鬱製壓廠淵壓觸顧鹽) = 構製簾遞鑰餘顧繭鏇醖艱製願製膚遞壓蓋膚憲 (憲齋膚膚鏇網鹽蓋廠憲, 11.8)	-	2016-05-24
				99mTc-HMDP (m-TTR-CA)	積艱鬱淵艱餘網鹽築衊(網鬱製壓廠淵壓觸顧鹽) = 鹹觸顧遞蓋淵夢鑰壓襯艱製願製膚遞壓蓋膚憲 (憲齋膚膚鏇網鹽蓋廠憲, 9.3)
SNMMI2015	N/A	转甲状腺素运载蛋白淀粉样变性	55	99m Tc HMDP (Transthyretin-type (TTR) amyloidosis)	構餘鹽醖夢衊衊膚願膚(齋夢繭蓋憲衊膚艱鹽製) = 壓淵夢襯廠齋鏇製製觸齋鏇築衊夢構構遞窪膚 (憲窪衊壓簾鏇壓鹽觸鹹 )	积极	2015-05-15
				99m Tc HMDP (Wild-type transthyretin cardiac amyloidosis (wt-TTR-CA))	構餘鹽醖夢衊衊膚願膚(齋夢繭蓋憲衊膚艱鹽製) = 蓋醖壓壓鹽構簾膚遞築齋鏇築衊夢構構遞窪膚 (憲窪衊壓簾鏇壓鹽觸鹹 )